Literature DB >> 25355876

T cell epitope clustering in the highly immunogenic BZLF1 antigen of Epstein-Barr virus.

Melissa J Rist1, Michelle A Neller2, Jacqueline M Burrows2, Scott R Burrows3.   

Abstract

UNLABELLED: Polymorphism in the human leukocyte antigen (HLA) loci ensures that the CD8(+) T cell response to viruses is directed against a diverse range of antigenic epitopes, thereby minimizing the impact of virus escape mutation across the population. The BZLF1 antigen of Epstein-Barr virus is an immunodominant target for CD8(+) T cells, but the response has been characterized only in the context of a limited number of HLA molecules due to incomplete epitope mapping. We have now greatly expanded the number of defined CD8(+) T cell epitopes from BZLF1, allowing the response to be evaluated in a much larger proportion of the population. Some regions of the antigen fail to be recognized by CD8(+) T cells, while others include clusters of overlapping epitopes presented by different HLA molecules. These highly immunogenic regions of BZLF1 include polymorphic sequences, such that up to four overlapping epitopes are impacted by a single amino acid variation common in different regions of the world. This focusing of the immune response to limited regions of the viral protein could be due to sequence similarity to human proteins creating "immune blind spots" through self-tolerance. This study significantly enhances the understanding of the immune response to BZLF1, and the precisely mapped T cell epitopes may be directly exploited in vaccine development and adoptive immunotherapy. IMPORTANCE: Epstein-Barr virus (EBV) is an important human pathogen, associated with several malignancies, including nasopharyngeal carcinoma and Hodgkin lymphoma. T lymphocytes are critical for virus control, and clinical trials aimed at manipulating this arm of the immune system have demonstrated efficacy in treating these EBV-associated diseases. These trials have utilized information on the precise location of viral epitopes for T cell recognition, for either measuring or enhancing responses. In this study, we have characterized the T cell response to the highly immunogenic BZLF1 antigen of EBV by greatly expanding the number of defined T cell epitopes. An unusual clustering of epitopes was identified, highlighting a small region of BZLF1 that is targeted by the immune response of a high proportion of the world's population. This focusing of the immune response could be utilized in developing vaccines/therapies with wide coverage, or it could potentially be exploited by the virus to escape the immune response.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25355876      PMCID: PMC4301143          DOI: 10.1128/JVI.02642-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

Review 1.  Epitope clusters in the major outer membrane protein of Chlamydia trachomatis.

Authors:  S K Kim; R DeMars
Journal:  Curr Opin Immunol       Date:  2001-08       Impact factor: 7.486

2.  Potent T cell response to a class I-binding 13-mer viral epitope and the influence of HLA micropolymorphism in controlling epitope length.

Authors:  Kate J Green; John J Miles; Judy Tellam; Wendy J M van Zuylen; Geoff Connolly; Scott R Burrows
Journal:  Eur J Immunol       Date:  2004-09       Impact factor: 5.532

3.  Evidence for coiled-coil dimer formation by an Epstein-Barr virus transactivator that lacks a heptad repeat of leucine residues.

Authors:  E Flemington; S H Speck
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

4.  Sequence analysis of EBV immediate-early gene BZLF1 and BRLF1 in lymphomas.

Authors:  Ying Yang; Yuping Jia; Yun Wang; Xiaofeng Wang; Zhifu Sun; Bing Luo
Journal:  J Med Virol       Date:  2014-02-25       Impact factor: 2.327

5.  Peptide motifs of HLA-A1, -A11, -A31, and -A33 molecules.

Authors:  K Falk; O Rötzschke; M Takiguchi; B Grahovac; V Gnau; S Stevanović; G Jung; H G Rammensee
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

6.  An enhancer within the divergent promoter of Epstein-Barr virus responds synergistically to the R and Z transactivators.

Authors:  M A Cox; J Leahy; J M Hardwick
Journal:  J Virol       Date:  1990-01       Impact factor: 5.103

7.  Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy.

Authors:  Tobias Krüger; Oliver Schoor; Claudia Lemmel; Bjoern Kraemer; Christian Reichle; Jörn Dengjel; Toni Weinschenk; Margret Müller; Jörg Hennenlotter; Arnulf Stenzl; Hans-Georg Rammensee; Stefan Stevanović
Journal:  Cancer Immunol Immunother       Date:  2004-12-31       Impact factor: 6.968

8.  Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism.

Authors:  S Zalani; E Holley-Guthrie; S Kenney
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

9.  CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells.

Authors:  Victoria A Pudney; Alison M Leese; Alan B Rickinson; Andrew D Hislop
Journal:  J Exp Med       Date:  2005-01-31       Impact factor: 14.307

Review 10.  Cellular responses to viral infection in humans: lessons from Epstein-Barr virus.

Authors:  Andrew D Hislop; Graham S Taylor; Delphine Sauce; Alan B Rickinson
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

View more
  4 in total

Review 1.  Gene sharing between Epstein-Barr virus and human immune response genes.

Authors:  David H Dreyfus
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

2.  Hepatitis D Virus-Specific CD8+ T Cells Have a Memory-Like Phenotype Associated With Viral Immune Escape in Patients With Chronic Hepatitis D Virus Infection.

Authors:  Helenie Kefalakes; Christopher Koh; John Sidney; Georgios Amanakis; Alessandro Sette; Theo Heller; Barbara Rehermann
Journal:  Gastroenterology       Date:  2019-01-18       Impact factor: 22.682

3.  B.1.1.7 (Alpha) variant is the most antigenic compared to Wuhan strain, B.1.351, B.1.1.28/triple mutant and B.1.429 variants.

Authors:  Manojit Bhattacharya; Ashish Ranjan Sharma; Bidyut Mallick; Sang-Soo Lee; Eun-Min Seo; Chiranjib Chakraborty
Journal:  Front Microbiol       Date:  2022-08-12       Impact factor: 6.064

4.  Immunoinformatics prediction of potential B-cell and T-cell epitopes as effective vaccine candidates for eliciting immunogenic responses against Epstein-Barr virus.

Authors:  Fisayo A Olotu; Mahmoud E S Soliman
Journal:  Biomed J       Date:  2021-06-19       Impact factor: 4.910

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.